A U.S. appeals court has remanded parts of the patent dispute between Guardant Health and TwinStrand Biosciences back to the Patent Trial and Appeal Board (PTAB) for further consideration. The court asked the PTAB to reassess validity of one of TwinStrand’s patents under a different statutory framework, potentially altering the scope of previous damage findings. The litigation stems from jury findings that Guardant willfully infringed TwinStrand patents covering duplex consensus sequencing error suppression; damages had been calculated at roughly $83.4 million and a 6 percent royalty rate. The remand lets the PTAB re-evaluate patent validity, a procedural development that could reduce Guardant’s exposure if the board reaches different conclusions.